|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||1,951.00 - 1,978.50|
|52 Week Range||1,426.00 - 2,025.00|
|Beta (5Y Monthly)||0.63|
|PE Ratio (TTM)||30.06|
|Forward Dividend & Yield||50.00 (2.62%)|
|Ex-Dividend Date||Sep. 29, 2021|
|1y Target Est||N/A|
Roxadustat, FibroGen (FGEN) and Astellas' candidate for symptomatic anemia of chronic kidney disease, secures EU approval. The drug is to be sold in Europe under the brand name Evrenzo.
Japanese shares closed lower on Monday, as investors locked in gains after a recent rally, although the losses were limited by a positive finish from local drugmakers. The Nikkei had jumped 2.1% on Friday to close at the 29,000-level for the first time since May 10, while Wall Street finished with marginal gains.
The FDA accepts Seagen (SGEN) and Astellas' two sBLAs for Padcev under a priority review to treat patients with locally advanced or metastatic urothelial carcinoma. A verdict is pending on Aug 17, 2021.